CR20180583A - Anticuerpos antifactor de la coagulación xi - Google Patents

Anticuerpos antifactor de la coagulación xi

Info

Publication number
CR20180583A
CR20180583A CR20180583A CR20180583A CR20180583A CR 20180583 A CR20180583 A CR 20180583A CR 20180583 A CR20180583 A CR 20180583A CR 20180583 A CR20180583 A CR 20180583A CR 20180583 A CR20180583 A CR 20180583A
Authority
CR
Costa Rica
Prior art keywords
antibodies
antifactor
coagulation
fxi
coagulation factor
Prior art date
Application number
CR20180583A
Other languages
English (en)
Inventor
Elizabeth Oldham
Mohammad Tabrizifard
Kenneth P Ellsworth
Dietmar Seiffert
Zhu Chen
James Milligan
Bianka Prinz
Vaishnavi Ganti
Original Assignee
Merck Sharp & Dohme
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Adimab Llc filed Critical Merck Sharp & Dohme
Publication of CR20180583A publication Critical patent/CR20180583A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se describen anticuerpos que se unen al dominio apple 3 del factor de la coagulación humano XI e inhiben la activación del FXI por el factor de la coagulación XIIa, así como la activación del FXI por el FXa.
CR20180583A 2016-06-14 2017-06-12 Anticuerpos antifactor de la coagulación xi CR20180583A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14
PCT/US2017/036940 WO2017218371A1 (en) 2016-06-14 2017-06-12 Anti-coagulation factor xi antibodies

Publications (1)

Publication Number Publication Date
CR20180583A true CR20180583A (es) 2019-07-02

Family

ID=59078269

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180583A CR20180583A (es) 2016-06-14 2017-06-12 Anticuerpos antifactor de la coagulación xi

Country Status (27)

Country Link
US (6) US10676536B2 (es)
EP (1) EP3469002A1 (es)
JP (2) JP7022081B2 (es)
KR (2) KR102379580B1 (es)
CN (2) CN116425879A (es)
AR (1) AR108717A1 (es)
AU (3) AU2017286432B2 (es)
BR (1) BR112018075858A2 (es)
CA (2) CA3025869A1 (es)
CL (1) CL2018003565A1 (es)
CO (1) CO2018013434A2 (es)
CR (1) CR20180583A (es)
DO (1) DOP2018000284A (es)
EA (1) EA201892716A1 (es)
EC (1) ECSP18091593A (es)
GE (1) GEP20227382B (es)
IL (1) IL263272A (es)
JO (1) JOP20180121A1 (es)
MA (1) MA45234A (es)
MX (1) MX2018015757A (es)
NI (1) NI201800134A (es)
PE (1) PE20190416A1 (es)
PH (1) PH12018502586A1 (es)
SG (2) SG11201810763TA (es)
TN (1) TN2018000417A1 (es)
TW (2) TWI802193B (es)
WO (1) WO2017218371A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017218371A1 (en) * 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
WO2018116255A1 (en) 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
US20230220111A1 (en) * 2020-07-02 2023-07-13 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
AU2021302199A1 (en) * 2020-07-03 2023-02-23 Suzhou Alphamab Co., Ltd. Coagulation factor XI (FXI) binding protein
JP2024509701A (ja) * 2021-02-09 2024-03-05 アークス セラピューティクス エーエス 抗ｓ１００ａ４ヒト化抗体、使用及び方法
WO2023098637A1 (zh) * 2021-11-30 2023-06-08 苏州康宁杰瑞生物科技有限公司 预防和/或治疗血栓栓塞性疾病的方法

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
KR100483494B1 (ko) 1998-12-01 2005-04-15 프로테인 디자인 랩스 인코포레이티드 감마 인터페론에 대한 인간화 항체
US7323311B2 (en) 2000-03-03 2008-01-29 Cambridge Antibody Technology Limited Methods of obtaining a specific binding member that binds eotaxin
WO2006069036A2 (en) 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
GEP20104887B (en) 2003-07-15 2010-02-10 Medarex Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
EP1957539B1 (en) 2005-12-08 2013-04-17 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
CN103204931B (zh) 2005-12-08 2016-08-03 米德列斯公司 抗岩藻糖基-gm1的人单克隆抗体及使用抗岩藻糖基-gm1抗体的方法
EP2024394B1 (en) 2006-06-06 2014-11-05 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
CN103524619B (zh) 2006-08-03 2016-10-05 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
MX344415B (es) 2007-09-14 2016-12-15 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8828382B2 (en) 2007-09-26 2014-09-09 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor binding proteins
LT3002298T (lt) * 2007-11-21 2019-12-10 Univ Oregon Health & Science Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
EP2313434A4 (en) 2008-07-31 2013-03-27 Univ California NEUTRALIZING ANTIBODIES OF BOTULINIC NEUROTOXINS
LT2350304T (lt) 2008-10-31 2017-02-10 Janssen Biotech, Inc. Toll tipo receptoriaus 3 antagonistai
US9403904B2 (en) 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
ES2720594T3 (es) 2008-12-18 2019-07-23 Univ Oregon Health & Science Anticuerpos anti-fXI y métodos de uso
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
CN102459342B (zh) 2009-04-27 2015-01-07 协和发酵麒麟株式会社 用于治疗血液肿瘤的抗il-3ra抗体
WO2011045704A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
JP6007420B2 (ja) 2009-11-04 2016-10-12 ファブラス エルエルシー 親和性成熟に基づく抗体最適化方法
EP2516624B1 (en) 2009-12-23 2020-02-05 Merck Sharp & Dohme Corp. Cell line 3m
WO2011097329A2 (en) * 2010-02-03 2011-08-11 Trilogy Ip Holdings, Inc. Mobile communication plan offerings
CN103282560B (zh) 2010-07-16 2016-08-03 阿迪马布有限责任公司 抗体文库
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
CA2818548A1 (en) 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
IL310186A (en) 2011-01-06 2024-03-01 Takeda Pharmaceuticals Co KALLIKREIN PLASMA BINDING PROTEINS
JP6082997B2 (ja) 2011-04-01 2017-02-22 メモリアル スローン−ケタリング キャンサー センター Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
HUE031089T2 (en) 2012-04-13 2017-06-28 Rottapharm Biotech Srl Anti-ADAMTS-5 antibody, derivatives and uses
US9783614B2 (en) 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
WO2013173255A2 (en) 2012-05-17 2013-11-21 Sorrento Therapeutics Inc. Antigen binding proteins that bind egfr
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US20160319032A1 (en) 2013-10-01 2016-11-03 Medlmmune Limited Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
BR112016021576A2 (pt) 2014-03-20 2017-10-10 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases ?anticorpo da proteína e2 de vírus anti-hepatite c ou fragmento do anticorpo que se liga ao antígeno da mesma, ácido nucleico, e, medicamento?
RU2764981C1 (ru) 2014-06-03 2022-01-24 ИксБиотеч Инк. Композиции и способы лечения и предупреждения инфекций, вызванных Staphylococcus aureus
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
ES2899227T3 (es) 2015-04-07 2022-03-10 Alector Llc Anticuerpos anti sortilina y métodos de uso de los mismos
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
RU2021129189A (ru) 2016-01-22 2021-11-15 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
WO2017218371A1 (en) * 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
KR20190075920A (ko) 2016-09-20 2019-07-01 바이엘 파마 악티엔게젤샤프트 인자 xi에 대한 신규 항체 및 그의 용도

Also Published As

Publication number Publication date
IL263272A (en) 2018-12-31
TWI802193B (zh) 2023-05-11
ECSP18091593A (es) 2019-01-31
KR20210021124A (ko) 2021-02-24
US11485794B2 (en) 2022-11-01
MA45234A (fr) 2019-04-17
US11512142B2 (en) 2022-11-29
TN2018000417A1 (en) 2020-06-15
US11661460B2 (en) 2023-05-30
SG11201810763TA (en) 2018-12-28
DOP2018000284A (es) 2019-01-31
US20200255542A1 (en) 2020-08-13
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
AU2024201084A1 (en) 2024-03-14
CN109476758B (zh) 2023-05-23
CN116425879A (zh) 2023-07-14
CN109476758A (zh) 2019-03-15
US11479615B2 (en) 2022-10-25
AU2020210233B2 (en) 2024-03-07
KR102218714B1 (ko) 2021-02-24
JP2019521978A (ja) 2019-08-08
US20200270364A1 (en) 2020-08-27
JP2021101720A (ja) 2021-07-15
NI201800134A (es) 2019-03-05
CA3172367A1 (en) 2017-12-21
MX2018015757A (es) 2019-05-30
WO2017218371A1 (en) 2017-12-21
JOP20180121A1 (ar) 2018-12-12
SG10202103120UA (en) 2021-05-28
TWI752964B (zh) 2022-01-21
AR108717A1 (es) 2018-09-19
AU2017286432A1 (en) 2018-12-06
AU2017286432B2 (en) 2020-09-24
CL2018003565A1 (es) 2019-03-22
GEP20227382B (en) 2022-05-25
PH12018502586A1 (en) 2019-10-07
TW201802120A (zh) 2018-01-16
BR112018075858A2 (pt) 2019-04-02
AU2020210233A1 (en) 2020-08-20
CO2018013434A2 (es) 2018-12-28
US20170355780A1 (en) 2017-12-14
US20200317811A1 (en) 2020-10-08
JP7022081B2 (ja) 2022-02-17
EA201892716A1 (ru) 2019-05-31
US20200308302A1 (en) 2020-10-01
CA3025869A1 (en) 2017-12-21
EP3469002A1 (en) 2019-04-17
TW202214702A (zh) 2022-04-16
JP7277500B2 (ja) 2023-05-19
KR20190018504A (ko) 2019-02-22
KR102379580B1 (ko) 2022-03-29
PE20190416A1 (es) 2019-03-19

Similar Documents

Publication Publication Date Title
CO2018013434A2 (es) Anticuerpos antifactor de la coagulación xi
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
MX2021000027A (es) Anticuerpos anti-factor de la coagulacion xi.
CO2017008824A2 (es) Heterociclos bicíclicos como inhibidores de fgfr4
EA202092435A3 (ru) Моноклональные антитела против bcma
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA202091540A1 (ru) Антитела к lilrb2
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
DOP2015000269A (es) Composiciones y métodos para alterar la señalización del segundo mensajero
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
CR20150578A (es) Heterociclos bicíclicos como inhibidores de fgfr
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
EA202092609A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201991997A1 (ru) Комбинированная терапия
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37